Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis-Reference-Cited by-同舟云学术

Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis

Published:2023-08 Issue:5 Volume:116 Page:1091-1099
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Rimner Andreas^ORCID,Moore Zachary R.,Lobaugh Stephanie,Geyer Alexander,Gelblum Daphna Y.,Abdulnour Raja-Elie E.,Shepherd Annemarie F.,Shaverdian Narek,Wu Abraham J.,Cuaron John,Chaft Jamie E.,Zauderer Marjorie G.,Eng Juliana,Riely Gregory J.,Rudin Charles M.,Els Nicholas Vander,Chawla Mohit,McCune Megan,Li Henry,Jones David R.,Sopka Dennis M.,Simone Charles B.,Mak Raymond,Weinhouse Gerald L.,Liao Zhongxing,Gomez Daniel R.,Zhang Zhigang,Paik Paul K.

Funder

Boehringer Ingelheim

National Institutes of Health

Memorial Sloan Kettering Cancer Center Fiona and Stanley Druckenmiller Center for Lung Cancer Research

National Cancer Institute

Boehringer Ingelheim Corp USA

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference34 articles.

1. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study;Yorke;Int J Radiat Oncol Biol Phys,2005